; and (II) in clause (ii), by striking subparagraph (B)(iii) and inserting subparagraph (B)(ii) ; and (iv) in subparagraph (E)— (I) by striking clause (i); and (II) by redesignating clauses (ii) and (iii) as clauses (i) and (ii), respectively; and (B) in paragraph (5)(A), by striking planted before January 1, 2027, or is grafted before such date to a plant that has already been planted, and inserting planted or grafted . (2) Section 460(c)(6)(B) of such Code is amended by striking which and all that follows through the period and inserting which has a recovery period of 7 years or less. . (c) Effective date The amendments made by this section shall take effect as if included in section 13201 of Public Law 115–97 . 304. Principal negotiating objectives of the United States relating to trade in covered pharmaceutical products Section 102(b) of the Bipartisan Congressional Trade Priorities and Accountability Act of 2015 ( 19 U.S.C. 4201(b) ) is amended by adding at the end the following: (23) Trade in covered pharmaceutical products (A) In general It is the objective of the United States to negotiate a plurilateral agreement among trusted allies relating to trade in covered pharmaceutical products to which section 103(b) will apply, for which the principal negotiating objectives of the United States are the following: (i) To ensure that a party to the agreement adopts and maintains measures to eliminate the imposition or reimposition of tariffs on imports of such products, particularly in the event of a declared emergency. (ii) To ensure that a party to the agreement— (I) will reduce or eliminate regulatory and other technical barriers in the pharmaceutical sector; (II) will promote expedited approval of facilities for the production of such products being built by business enterprises that operate one or more such facilities in the territory of the party